GILTERITINIB | GILTERITINIB | ATC L01EX13
ANTINEOPLASTIC TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH A FLT3 MUTATION TYROSINE KINASES INHIBITOR INHIBITOR OF FMS-LIKE TYROSINE KINASE 3 (FLT3) INCLUDING FLT3-D835Y AND FLT3-ITD-D835Y MUTATIONS | ORAL | Cmax 0.67 MICROMOLAR Tmax 5 HOUR VD 1092 LITER PPB 94 PERCENT Cl 14.85 LITER / HOUR HT 113 HOUR SOLUBILITY SPARINGLY SOLUBLE IN WATER | FMS-LIKE TYROSINE KINASE 3 (FLT3) PDB 6JQR (CRYSTAL STRUCTURE OF FLT3 IN COMPLEX WITH GILTERITINIB) LIGAND CODE = C6F (link to the list of PDB complexes) Download experimental 3D coordinates of C6F with added hydrogens | Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |